- Home
- CC vs VRNA Comparison
CC vs VRNA Comparison
Compare CC & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CC
- VRNA
- Stock Information
- Founded
- CC 2014
- VRNA 2005
- Country
- CC United States
- VRNA United Kingdom
- Employees
- CC N/A
- VRNA N/A
- Industry
- CC Major Chemicals
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- CC Industrials
- VRNA Health Care
- Exchange
- CC Nasdaq
- VRNA Nasdaq
- Market Cap
- CC 2.9B
- VRNA 3.4B
- IPO Year
- CC N/A
- VRNA 2017
- Fundamental
- Price
- CC $19.40
- VRNA $51.89
- Analyst Decision
- CC Buy
- VRNA Strong Buy
- Analyst Count
- CC 8
- VRNA 7
- Target Price
- CC $23.75
- VRNA $50.57
- AVG Volume (30 Days)
- CC 1.6M
- VRNA 1.4M
- Earning Date
- CC 02-26-2025
- VRNA 02-27-2025
- Dividend Yield
- CC 5.16%
- VRNA N/A
- EPS Growth
- CC N/A
- VRNA N/A
- EPS
- CC 0.50
- VRNA N/A
- Revenue
- CC $5,749,000,000.00
- VRNA $5,624,000.00
- Revenue This Year
- CC N/A
- VRNA N/A
- Revenue Next Year
- CC $4.57
- VRNA $550.30
- P/E Ratio
- CC $38.63
- VRNA N/A
- Revenue Growth
- CC N/A
- VRNA 1127.95
- 52 Week Low
- CC $15.10
- VRNA $11.39
- 52 Week High
- CC $32.48
- VRNA $55.42
- Technical
- Relative Strength Index (RSI)
- CC 59.01
- VRNA 64.25
- Support Level
- CC $18.60
- VRNA $43.44
- Resistance Level
- CC $19.43
- VRNA $55.42
- Average True Range (ATR)
- CC 0.67
- VRNA 3.32
- MACD
- CC 0.32
- VRNA 0.40
- Stochastic Oscillator
- CC 95.83
- VRNA 70.52
About CC Chemours Company (The)
The Chemours Co is a global provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.